Characteristic | Healthy controls | Survivors (90 days) | Non-survivors (90 days) | p value* (survivors vs non-survivors) |
---|---|---|---|---|
Number of patients | 18 | 14 | 34 | |
Gender, male | 15 (83%) | 11 (79%) | 24 (71%) | |
Age (years) | 53 [25–58] | 57 [47–74] | 75 [67–86] | 0.0014 |
Type of infection | – | |||
VAP/HAP | – | 11 (79%) | 22 (65%) | 0.35 |
HCAP | – | 3 (21%) | 12 (35%) | |
Severity of illness at admission | ||||
APACHE II score | – | 16 [14–21] | 23 [18–27] | 0.009 |
SOFA score | – | 10 [8.8–11] | 10 [9–12] | 0.41 |
Secondary infections | – | 9 (64%) | 17 (50%) | 0.36 |
New sepsis episode | – | 7 (50%) | 16 (47%) | 0.85 |
Charlson comorbidity index | – | 4 [1–5] | 6 [5–9] | 0.002 |
Length of hospital stay | – | 36 [24–48] | 14 [8–28] | 0.003 |
Length of ICU stay | – | 26 [13–37] | 15 [8–28] | 0.16 |
Leukocytes (× 109/L) | – | 13.9 [7.5–16.0] | 13.8 [10.6–20.4] | 0.32 |
PMN-MDSCs (% of leukocytes) | 2.1 [0.74–3.1] | 22 [6–44] | 22 [8–37] | 0.96 |
M-MDSCs (% of leukocytes) | 0.96 [0.46–1.5] | 4.6 [2.6–6.5] | 2.9 [1.8–4.1] | 0.052 |
Lactate (mmol/L) | – | 1.4 [0.85–2.2] | 2.8 [1.6–2.8] | 0.02 |
CRP (mg/L) | – | 130 [40–174] | 144 [78–184] | 0.63 |
IL-6 (pg/mL) | – | 29 [19–52] | 31 [17–73] | 0.73 |
Ferritin (ng/mL) | – | 501 [349–675] | 748 [437–1478] | 0.14 |